Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat versus placebo in children with sickle cell disease
NL-OMON61617Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Etavopivat with Placebo (2 arms). Primary endpoint: Annualized rate of adjudicated vaso-occlusive crisis events with a medical contact. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON61617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61617.